GSK receives approval from the USFDA for Jemperli plus chemotherapy for dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Published Date: 04 Aug 2023

In adult patients with dMMR recurrent or advanced endometrial cancer who have advanced on or, Jemperli is already approved as a monotherapy in the US.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot